Adicet Bio Earnings Call Transcripts
Fiscal Year 2025
-
Gamma delta CAR T therapies show strong safety and efficacy in autoimmune diseases, with ongoing responses and immune reset in LN and SLE. Multiple data readouts and regulatory milestones are expected next year, supported by robust manufacturing and a solid cash runway.
-
Phase 1 results for ADI-001 in LN and SLE showed rapid, durable clinical responses, robust immune reset, and a favorable safety profile, with all patients discontinuing immunosuppressants and most achieving complete or partial renal response. The off-the-shelf, outpatient potential differentiates ADI-001 from autologous therapies, supporting plans for a pivotal single-arm trial in 2026.
-
Off-the-shelf gamma delta 1 CAR T therapies show strong safety and efficacy in autoimmune diseases, with ADI-001 targeting multiple indications and aiming for outpatient use. Key clinical data are expected this year, and a PSMA-targeted oncology program is advancing.
-
Off-the-shelf Gamma-delta CAR-T therapies show promise for autoimmune diseases, offering safety, convenience, and robust B cell depletion. Initial clinical data for SLE and LN are expected soon, with endpoints focused on remission and steroid reduction. Manufacturing supports large-scale dosing.
-
The session highlighted a diversified pipeline of off-the-shelf γδ one CAR T-cell therapies in autoimmune and oncology, with key data readouts expected in the second half of the year. Programs target high unmet needs, leveraging unique cell properties for efficacy and safety.
-
Gamma delta CAR T cell therapies are advancing in both autoimmune and solid tumor indications, with off-the-shelf convenience, strong safety, and tissue targeting. Key data from lupus nephritis, SLE, and RCC programs are expected in the second half, supported by robust financials and positive regulatory engagement.
-
Gamma delta T cell therapies show strong safety and efficacy, with rapid enrollment in both autoimmune and oncology programs. Multiple data readouts are expected this year, supported by robust funding into 2026. Manufacturing is efficient, and commercial prospects are strong.
Fiscal Year 2024
-
Gamma delta 1 T cell therapies show strong tissue targeting, safety, and scalable manufacturing, with a strategic pivot from lymphoma to autoimmune diseases and solid tumors. Multiple clinical programs are advancing, with key data readouts and expansion into new indications expected in 2024 and 2025.
-
The company is advancing CAR gamma delta one T cell therapies for oncology and autoimmune diseases, with strong proof of concept in NHL/MCL and a differentiated safety and manufacturing profile. Key clinical data from both autoimmune and solid tumor programs are expected in the first half of next year.
-
New data show ADI-001 achieves robust trafficking and complete B-cell depletion in tissues, outperforming antibody therapies that only deplete B cells in blood. The therapy is advancing in four autoimmune indications, with initial clinical data expected in early 2025.
-
Announced strategic focus on autoimmune diseases for ADI-001, with strong clinical data supporting this shift. ADI-270 advances as a differentiated solid tumor therapy, with both programs expecting key data in H1 next year. Well-funded through H2 2026.
-
Gamma delta CAR T cells show promise in autoimmune diseases due to consistent B-cell depletion, superior safety, and tissue tropism, with clinical trials expanding to multiple indications and data expected in the first half of next year. In oncology, ADI-270 leverages unique mechanisms for solid tumor targeting and efficacy.
-
Gamma delta 1 T cell therapies offer off-the-shelf dosing, strong tissue tropism, and improved safety for autoimmune and oncology indications. Key programs target lupus nephritis and renal cell carcinoma, with robust manufacturing and funding supporting multiple upcoming data readouts.